A recent study published in the Journal of the American Geriatrics Society explores the potential link between long-term non-steroidal anti-inflammatory drug (NSAID) use and the risk of developing dementia. The study suggests that extended NSAID usage may lower dementia risk, with genetic factors playing a role in the treatment’s effectiveness.
The Role of Inflammation in Dementia
Dementia is characterized by a gradual decline in brain function, often linked to various pathophysiological changes, including inflammation. Chronic inflammation, driven by factors like hypertension, atherosclerosis, and the accumulation of amyloid-β and tau proteins, is a key contributor to the onset of dementia. These factors damage blood vessels, impair the blood-brain barrier, and promote the buildup of harmful proteins that disrupt brain function.
NSAIDs and Dementia Risk
NSAIDs, widely used for their anti-inflammatory and analgesic properties, work by inhibiting cyclooxygenase (COX) enzymes. Previous studies in animals suggested that NSAIDs might help reduce amyloid-β plaques in the brain. However, while one meta-analysis found a reduced risk of dementia among NSAID users, other research showed no such effect, highlighting the inconsistency in findings.
Few large-scale, long-term studies have investigated the relationship between prolonged NSAID use and dementia risk, making this new study an important contribution to the field.
The Rotterdam Study: Methodology and Findings
The study utilized data from the Rotterdam Study, a long-running cohort study in the Netherlands that began in 1990 with participants aged 55 and older. Initially enrolling 7,983 individuals, the study eventually included 14,926 participants. Follow-up examinations are conducted every four years to monitor health developments.
At the start of the study, 13,507 participants were dementia-free and consented to be tracked through medical records. During the follow-up period, approximately 81% of participants used NSAIDs, totaling nearly 94,000 months of cumulative NSAID use. Women were more likely than men to report long-term use, and those using NSAIDs long-term were more likely to have a higher body mass index (BMI) and a diagnosis of diabetes.
Key Study Findings
After a mean follow-up period of 14.5 years, 17.8% of participants were diagnosed with dementia, with 73.4% of those cases being classified as Alzheimer’s disease (AD). The study found that while short- and intermediate-term use of NSAIDs (less than two years) was associated with an increased risk of dementia, long-term use (over two years) appeared to lower the risk.
Interestingly, NSAIDs without amyloid-β-lowering properties were more strongly associated with a reduced dementia risk than those that did lower amyloid-β. Moreover, long-term NSAID use was beneficial only for those without the apolipoprotein ε4 (APOE-ε4) gene variant, which is a known risk factor for Alzheimer’s disease.
Conclusion
The findings suggest that long-term NSAID use, specifically for over two years, may offer a protective effect against dementia, with the duration of use being more important than the cumulative dose. However, the study also underscores the need for further research to better understand the potential of anti-inflammatory drugs in dementia prevention, especially in genetically diverse populations.
The study highlights that while prolonged NSAID use could have preventive benefits, its impact varies by genetic factors, with those carrying the APOE-ε4 allele showing no benefit. Further investigation is necessary to confirm these results and explore the therapeutic potential of NSAIDs for dementia prevention.
Related topic:
Ultra-Processed Foods Linked to Heart Disease Risk
Micronutrient Deficiencies and Excesses Affecting Pacific Children
Replacing Butter with Plant Oils Linked to Lower Mortality Risk
